JY BioMed Secures Dual FDA Recognition, Establishing Early Leadership in the Exosome Space

Parallel Clinical Development of Parent Cell Platform Builds Vertically Integrated Foundation

As the global exosome therapeutics market accelerates into a period of regulatory convergence, Taiwan-based biotechnology company JY BioMed today announced the completion of a dual FDA Drug Master File (DMF) filing strategy in January 2025 — covering both Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC, DMF 041078) and UC-MSC-derived Exosomes (DMF 041203). With both filings formally accepted by the U.S. FDA, JY BioMed stands among a select few biotechnology companies in Taiwan to hold dual FDA DMFs spanning UC-MSC and its derived exosome product, and is actively leveraging this regulatory foundation to advance Investigational New Drug (IND) application preparations.

Dual DMF Vertical Integration: Quality Traceability from Parent Cell to Derived Product

Together, the two DMFs form a complete "parent cell → derived exosome" vertically integrated platform. Manufacturing origin, quality controls, and stability data for the exosome are all established within the FDA DMF framework, with product quality directly traceable to the FDA-filed parent cell source material. While the majority of exosome-focused companies in Taiwan's current market lack comprehensive pharmaceutical-grade documentation, JY BioMed's regulatory standard far exceeds cosmetic-grade benchmarks — representing a regulatory and technical moat that few domestic exosome developers can replicate in the near term.

Parent Cell Clinical Trials: Human Safety Data Anchoring Exosome Development

JY BioMed's UC-MSC platform is currently under clinical investigation through multiple trials conducted under the oversight of both the U.S. FDA and Taiwan's TFDA, encompassing Phase 1 human safety evaluations targeting frailty and neurodegenerative diseases including Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). The systematic safety data accumulated at the parent cell level provides a critical scientific foundation for downstream exosome clinical development — a distinctive advantage that exosome-only developers do not possess.

Academic-Industry Collaboration with Taipei Medical University: Advancing Exosome Blood-Brain Barrier Penetration

Owing to their nanoscale dimensions (30–200 nm) and natural membrane architecture, exosomes possess unique capacity to traverse the blood-brain barrier (BBB), positioning them as a highly promising next-generation drug delivery platform for neurodegenerative diseases. JY BioMed has established a long-term academic-industry collaboration with Taipei Medical University (TMU), actively advancing preclinical research on exosome applications in Parkinson's disease, ALS, and pain management, progressively building the scientific evidence chain required for IND submission. The TMU collaboration spans multiple JY BioMed technology platforms — including ADC, GDT, and UC-MSC — forming a fully integrated academic-industry-research alliance from discovery through clinical development.

Ethan Shen, PhD, Founder & Chairman of JY BioMed, stated:

"The exosome market doesn't lack products — it lacks regulatory rigor. From parent cell to derived exosome, every step at JY BioMed is backed by complete FDA documentation. This is the most fundamental commitment of integrity we can make to future clinical partners and patients."

Regulatory-First Strategy: Advancing Toward IND Submission

JY BioMed stated that the company will continue to build out toxicology and process validation data sets in preparation for FDA IND submission, while actively engaging with TFDA on regenerative medicine regulatory pathways. Through a strategy of "regulatory leadership, technology lock-in, and clinical data support," JY BioMed aims to establish first-mover advantages in the exosome space ahead of formal global regulatory consolidation.

About JY BioMed

JY BioMed is a Taiwan-based multi-platform biotechnology company. Its core technology platforms span Heavy Chain Antibody-Drug Conjugates (HCAb-ADC), Gamma Delta T (GDT) cells, Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC), and Exosomes. The GDT platform has been licensed internationally; the ADC platform holds core patents on CEACAM6-targeting antibodies and related ADC technologies. Multiple technology platforms maintain long-term academic-industry collaborations with Taipei Medical University, spanning the full continuum from research exploration to clinical development.

In January 2025, JY BioMed filed dual FDA Type II Drug Master Files covering UC-MSC (DMF 041078) and UC-MSC-derived Exosomes (DMF 041203), establishing a vertically integrated platform with full quality traceability from parent cell to derived exosome product. Photo 1 / Courtesy of JY BioMed

In collaboration with Taipei Medical University, JY BioMed is advancing preclinical research on exosome applications in Parkinson's disease, ALS, and pain management, with a focus on the unique blood-brain barrier penetration capability of exosomes. Photo 2 / Courtesy of JY BioMed